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The myxovirus resistance (Mx) proteins are inter-
feron-induced dynamin GTPases that can inhibit a
variety of viruses. Recently, MxB, but not MxA, was
shown to restrict HIV-1 by an unknown mechanism
that likely occurs in close proximity to the host cell
nucleus and involves the viral capsid. Here, we pre-
sent the crystal structure of MxB and reveal determi-
nants involved in HIV-1 restriction. MxB adopts an
extended antiparallel dimer and dimerization, but
not higher-ordered oligomerization, is critical for
restriction. Although MxB is structurally similar to
MxA, the orientation of individual domains differs be-
tweenMxA andMxB, and their antiviral functions rely
on separate determinants, indicating distinct mecha-
nisms for virus inhibition. Additionally, MxB directly
binds the HIV-1 capsid, and this interaction depends
on dimerization and the N terminus of MxB as well as
the assembled capsid lattice. These insights estab-
lish a framework for understanding the mechanism
by which MxB restricts HIV-1.
INTRODUCTION
Myxovirus resistance protein 2 (MxB) is an interferon-induced in-
hibitor of HIV-1 infection (Goujon et al., 2013; Kane et al., 2013;
Liu et al., 2013). MxB was traditionally thought to function in
cell-cycle progression and regulation of nuclear import (King
et al., 2004; Mele´n et al., 1996). This antiviral function occurs
downstream of reverse transcription, decreasing the amount of
integrated viral DNA (Liu et al., 2013) and 2-long terminal repeat
(2-LTR) circular DNA (Goujon et al., 2013; Kane et al., 2013) that
marks translocation of the cytoplasmic reverse transcription
complex into the nucleus. These results suggest that MxB in-
hibits HIV-1 nuclear import or destabilizes nuclear viral DNA
(Goujon et al., 2013; Kane et al., 2013). MxB is highly homolo-
gous in sequence (63% identity) to MxA, whose antiviral activ-
ities are well established (Aebi et al., 1989; Hefti et al., 1999).
MxA restricts both DNA and RNA viruses, including influenza A
virus (Haller and Kochs, 2011). It has been shown that MxA inter-
feres with translocation of viral components between the cyto-Cell Host &plasm and the nucleus, potentially via binding to and causing
mislocalization of viral nucleocapsid protein (Kochs and Haller,
1999a, 1999b; Kochs et al., 2002b; Reichelt et al., 2004).
Both MxB and MxA are guanosine triphosphatases (GTPases)
that belong to the dynamin superfamily. Extensive structural,
biochemical, and cellular studies have revealed the function of
each MxA domain. The amino-terminal GTPase domain binds
and hydrolyzes GTP, while a bundle signaling element (BSE)
domain connects and transmits signals between the GTPase
and the stalk domains (Gao et al., 2011). The stalk domain is crit-
ical for oligomerization (Gao et al., 2010, 2011; Haller et al., 2010;
Kochs et al., 2002a). GTPase activity and oligomerization are
critical for viral inhibition by MxA (Daumke et al., 2010; Di Paolo
et al., 1999; Mele´n et al., 1992; Pavlovic et al., 1993; Schwemmle
et al., 1995).
Despite the similarity in sequence and architecture, MxB and
MxA work against different viruses and appear to have different
mechanisms of action. MxB restricts HIV-1, which is not among
the diverse range of viruses inhibited by MxA. MxB (715 amino
acids) harbors a 43 residue N-terminal extension that contains
a nuclear localization signal (NLS), which is critical for HIV-1 re-
striction (Kane et al., 2013;Mele´n et al., 1996). A shorter MxB iso-
form that initiates fromMet26 lacks the NLS and therefore would
not restrict HIV-1 (Mele´n et al., 1996). TheMxBN-terminal region
also contains anti-HIV-1 specificity determinants distinct from
the NLS (Busnadiego et al., 2014; Goujon et al., 2014; K.A.M.
et al., unpublished data). Besides the N-terminal differences,
MxB mutants that are unable to bind or hydrolyze GTP retain
the ability to restrict HIV-1 (Goujon et al., 2013; Kane et al.,
2013), which is contrary to theGTPase-dependent restriction ac-
tivity of MxA. Furthermore, instead of targeting the nucleocapsid
protein like MxA, the antiviral activity of MxB involves the HIV-1
capsid protein (CA), as CA mutations can counteract restriction
by MxB (Busnadiego et al., 2014; Goujon et al., 2014; Kane
et al., 2013; Liu et al., 2013). Though HIV-1 CA interacts with
many cellular factors, including CypA, TRIM5a, CPSF6, and
NUP153 (Ambrose and Aiken, 2014; Matreyek and Engelman,
2013), it remains to be determined if there is a direct interaction
between MxB and CA, or if other cellular factors mediate the
CA-dependent activity ofMxB. In addition, it is unknownwhether
MxB functions by forming MxA-like higher order oligomers
(Mele´n and Julkunen, 1997).
To provide insight into its mechanism of HIV-1 restriction, we
determined the crystal structure of MxB. The structure shows
that MxB has a similar architecture to MxA but with differentMicrobe 16, 627–638, November 12, 2014 ª2014 Elsevier Inc. 627
Figure 1. Structure of MxB84YRGK and Its Antiviral Activity
(A) Structure of the MxB dimer shown in two orientations, with protomers 1 and 2 colored in purple and yellow, respectively.
(B) Schematic (left) and structure (right) of an MxB protomer with residues of domain boundaries denoted and colored. The arrows in the schematic denote the
first and last visible residues in the structure.
(C) Superposition of protomer 1 and protomer 2 in two views.
(D) Cells expressing HA-taggedWTorMxBYRGKwere analyzed forMxB expression. Total cellular proteins were extracted, resolved by SDS-PAGE, and visualized
by western blotting with anti-HA antibody. WT MxB expression was set to 1. Results are the mean of threee independent experiments, with error bars denoting
standard error.
(E) Immunofluorescent microscopy of untransduced or MxB-expressing cells. Blue, nuclear DNA.
(F) Susceptibility of WT or MxBYRGK-expressing versus control (nontransduced) HOS cells to HIV-1 (dark gray), EIAV (light gray), or FIV (striped gray) infection.
Error bars denote 95% confidence intervals derived from seven independent experiments.
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studies that inform about the regions of MxB that are critical for
HIV-1 restriction. Our results reveal key differences between the
antiviral activities of MxA and MxB, demonstrating that these
closely related proteins have distinct mechanisms of action.
Importantly, our study establishes that MxB binds directly to
HIV-1 capsid assemblies and indicates that direct engagement
of the capsid lattice by the antiparallel MxB dimer is critical to
antiviral function.
RESULTS
Crystal Structure of MxB
To investigate the structural basis for HIV-1 restriction, we crys-
tallized an N-terminal truncation of MxB. To improve the solution
behavior of MxB, we deleted the first 83 amino acids, which are628 Cell Host & Microbe 16, 627–638, November 12, 2014 ª2014 Elspredicted to be unstructured, and introducedmutations into loop
2 of the stalk domain (YRGK487-490AAAA), as similar changes
improved the solution behavior of MxA (Gao et al., 2010, 2011).
This construct, MxB84YRGK, allowed for the purification of mono-
dispersed, dimeric protein that crystallized and diffracted X-rays
to 3.2 A˚ resolution. We solved the structure by molecular
replacement usingMxA as a search model and refined the struc-
ture to Rwork/Rfree of 26.5%/29.9% with one MxB dimer in the
asymmetric unit (Figure 1A). The detailed statistics are shown
in Table 1. Two MxB protomers form an extended antiparallel
dimer (Figure 1A). The GTPase and stalk domains are located
at either end of the MxB protomer, bridged by the BSE domain
that is composed of three helices originating from distinct re-
gions of the primary amino acid sequence (Figure 1B). Residues
84–92, 145–149, 231–237, 580–621, and 712–715 are disor-
dered in the structure. The structures of the correspondingevier Inc.
Table 1. Data Collection and Refinement Statistics
Data Collection
Wavelength (A˚) 0.9792
Space group P21
Cell Dimensions
a, b, c (A˚) 53.18, 80.78, 183.67
a, b, g () 90.00, 95.73, 90.00
Molecules/asymmetric unit 2
Resolution (A˚) 43.9–3.2 (3.26–3.20)a
Rmerge 0.087 (>1.0)
I/sI 16.1 (1.1)
Completeness (%) 94.7 (89.9)
Redundancy 5.4 (5.1)
Unique reflections 24,248
Refinement
Number of nonhydrogen atoms 9,082
Rwork/Rfree (%) 26.5/29.9
Average B factor 148
Root-Mean-Square Deviation (rmsd)
Bond lengths (A˚) 0.002
Bond angles () 0.6
Ramachandran Analysis
Preferred regions (%) 95.0
Allowed regions (%) 4.1
Outliers (%) 0.9
aValues in parenthesis are for highest-resolution shell.
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mean-square deviations (rmsd) ranging between 0.25 and
0.38 A˚ (Figure 1C). The overall rmsd of the two MxB protomers
is 1.7 A˚, which is substantially larger than that of the individual
domains, indicating flexibility at the linker regions connecting
the domains.
To characterize the physiological relevance of MxB84YRGK, we
assessed the antiviral activities of wild-type (WT) and mutant
MxB proteins. MxB was stably expressed with a C-terminal
hemagglutinin (HA) tag to facilitate its immunodetection in hu-
man osteosarcoma (HOS) cells, which were used previously to
assess the mechanism of HIV-1 restriction (Kane et al., 2013). In-
dependent of stimulation by interferon (IFN) a, HOS cells did not
detectably express endogenous MxB protein (K.A.M. et al., un-
published data). Immunofluorescent staining revealed that WT
MxB formed cytoplasmic puncta and localized to the nuclear
rim (Figure 1E), as described previously (Kane et al., 2013;
King et al., 2004; Mele´n et al., 1996). Although the MxB84YRGK
construct is presumably inactive due to loss of the N-terminal
NLS (Kane et al., 2013), we independently tested whether the
YRGK487-490AAAA mutation affected the antiviral activity of
full-length MxB. The mutant protein (MxBYRGK) was expressed
to about 80% of the level of WT MxB (Figure 1D) and, in contrast
to the punctate staining observed with the WT protein, MxBYRGK
exhibited more diffuse staining within the cytoplasm (Fig-
ure 1E). WTMxB restricted HIV-1 infection about 10-fold without
noticeably affecting the infectivity of equine infectious anemia
virus (EIAV) or feline immunodeficiency virus (FIV) (Figure 1F).Cell Host &MxBYRGK also significantly inhibited HIV-1 infection (6-fold).
The mutant protein restricted EIAV infection by about 3-fold
but remained inert against FIV. The gain-of-function against
EIAV could be due to the altered pattern of MxBYRGK subcellular
localization (Figure 1E). WT MxB, moreover, was reported in an
independent study to restrict EIAV at a level similar to that
observed here for MxBYRGK (Kane et al., 2013). In any case,
the solubility-enhancing YRGK487-490AAAA mutations used
for crystallographic studies did not significantly alter the ability
for MxB to restrict HIV-1.
BSE Hinge Communication Is Not Required for HIV
Restriction
Although the overall arrangement of individual protein domains is
similar between the MxA and MxB structures, large differences
in domain orientation are observed between the proteins (Fig-
ure 2A). The individual domain structures of the two proteins
are quite similar, with corresponding rmsd in the range of 0.8–
1.1 A˚, while the overall rmsd between MxA and MxB protomers
is greater than 6.4 A˚. The difference in domain orientations,
pivoted around two hinge regions connecting the domains, is
primarily responsible for the overall deviation between MxA
and MxB (Figure 2A).
We next tested the potential involvement of hinge communica-
tion inMxB function. Residues at the ends of the BSE are thought
to act as hinges that transfer signals between the GTPase and
stalk domains in dynamin superfamily proteins (Gao et al.,
2011; Prakash et al., 2000). We compared the structures and
sequences of MxA and MxB and identified key residues in
each of the two MxB hinges (Figure 2B). Hinge 1 has two loops
that connect the BSE to the stalk domain (residues 406–416
and 679–684). The highly conserved residue R689 on helix 3 of
the BSE contacts G408 and D410 on BSE loop 1. R689 also in-
teracts with the side chain of E681 on BSE loop 2. Hinge 2 pivots
around P387, which causes a kink in the a helix connecting the
GTPase domain and the BSE. MxB hinge mutants E681A and
R689A were expressed in HOS cells at levels similar to the WT
protein (Figures 2C and 2D) and significantly inhibited HIV-1
infection, by 10-fold and 5.5-fold, respectively (Figure 2E).
The corresponding MxA mutations, E632A and R640A, reduced
MxA oligomerization, GTPase activity, and antiviral activity (Gao
et al., 2011). These observations indicate that anti-HIV-1 activity
is not dependent on the transfer of information from the GTPase
domain to the stalk domain, which is consistent with data
showing that MxB antiviral function is independent of GTPase
activity (Goujon et al., 2013; Kane et al., 2013).
Dimerization, but Not Higher-Order Oligomerization, of
MxB Is Required for Antiviral Activity
MxB forms an antiparallel dimer with the dimer interface lying at
the center of the two protomers. It is composed of residues on
stalk helices 3 and 4 (Figure 3A). To be consistent with the
MxA/dynamin convention, we refer to the dimer interface as
interface 2 (Figure 3A). The buried surface area at this interface
is 1,074 A˚2, with symmetric hydrophobic contacts between
M567, L570, M574, and V578 of each protomer with M567,
L570, F647, and Y651 of the other protomer. The dimer is further
stabilized by hydrogen bonds between Q571 of each protomer
and Q644 of the other protomer (Figure 3B). We tested theMicrobe 16, 627–638, November 12, 2014 ª2014 Elsevier Inc. 629
Figure 2. MxB Hinge Mutations Do Not Abolish Antiviral Activity
(A) Superposition of MxA monomer (PDB ID: 3SZR; red) and MxB protomer 1 (purple), based on either GTPase domain (left) or stalk domain (right).
(B) Zoomed-in view of BSE domain with hinges and key residues highlighted.
(C–E) Cells expressingWT, E681A, or R689Amutant MxB were analyzed for (C) total expression, (D) subcellular localization, and (E) antiviral activity as described
in Figure 1. Relative expression values are an average of at least three independent blotting experiments, with error bars denoting standard error. Infection values
are the mean of five independent experiments, with error bars denoting 95% confidence intervals.
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an M574D mutation destabilized the dimerization interface.
MxB84YRGK eluted from a size-exclusion column at a volume
that corresponds to the molecular weight of an extended dimer
based on molecular weight standards. The M574D mutation
decreased dimerization, as the majority of MxB84YRGK/M574D
eluted at a volume corresponding to the molecular weight of
monomeric MxB (Figure 3C). This is consistent with the observa-
tion that the corresponding residue in MxA is critical for MxA
dimerization (Gao et al., 2010).
We tested the requirement of MxB dimerization for its antiviral
function. Interface 2mutantsM574D, Y651D, andM567D/L570D
were ineffective against HIV-1, each inhibiting infection 1.6-fold
or less, which did not differ significantly from EIAV or FIV (Fig-
ure 3D). The dimerization state of MxB appears to affect its
expression pattern, as the interface 2 mutants were expressed
at 30%–50% of the level of WT MxB (Figure 3E). The mutant
proteins also exhibited drastically altered localization compared
to WT MxB, as they stained throughout the cell, including prom-630 Cell Host & Microbe 16, 627–638, November 12, 2014 ª2014 Elsinent staining within the intranuclear space (Figure 3F). In a sepa-
rate study, we determined that the MxB GTPase mutant T151A,
which was expressed at38%ofWTMxB, displayed full restric-
tion activity (K.A.M. et al., unpublished data). Our findings
accordingly indicate that dimerization plays an important role
inMxB subcellular localization and is required for viral restriction.
MxB dimers can form higher-order assemblies by interdigi-
tating through the stalk and BSE regions as observed in MxA.
This mode of higher-order oligomerization is formed through
MxB crystal packing interactions (Figure 4A). Through this inter-
action, MxB dimers may assemble to form filaments. The MxB
dimer-dimer interface revealed in the crystal structure has a
buried surface area of > 2,500 A˚2. Following the convention for
MxA, we refer to the interface region at the beginning of stalk he-
lices as interface 1. Interaction at this interface is critical for MxA
function (Gao et al., 2010). Interface 1 involves the stalks from
one protomer of each interacting MxB dimer (designated proto-
mer 1 and protomer 10; the prime symbol denotes an adjacent
dimer) (Figure 4A). The interactions at this interface include theevier Inc.
Figure 3. The MxB Dimer Is Required for Antiviral Activity
(A) Dimer of MxB (top) with zoomed-in view of dimer interface in surface representation (bottom).
(B) Zoomed view of dimer interface with key residues shown as sticks.
(C) Size-exclusion chromatography analysis of MxB84YRGK (green), which elutes at a volume corresponding to a dimer, and MxB84YRGK/M574D (cyan), a majority of
which elutes at a volume corresponding to a monomer. Inset, SDS-PAGE of peak fractions corresponding to monomeric (lane 2 of each set) and dimeric (lane 1)
MxB.
(D) Antiviral activities of WT and interface 2 mutants of MxB. Activity assays are as described in Figure 1F. Results are an average of at least four independent
experiments, with error bars denoting 95% confidence intervals.
(E) Total mutant MxB expression levels relative toWTMxB (set to 1). Results are an average of three independent experiments, with error bars denoting standard
error.
(F) WT and mutant MxB localization as determined by confocal microscopy following antibody staining.
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both stalks (Figure 4A). This is further stabilized by a hydrogen
bond between E424 of protomer 1 and K663 of protomer 10.
To gain insight into higher-ordered oligomerization of MxB,
we analyzed how mutations in these interfaces alter MxB’s olig-
omerization state by cryoelectron microscopy (cryo-EM). An
assortment of structural assemblies was observed by cryo-EM
for the purified full-length WT MxB tagged with maltose-binding
protein (MBP-MxB). Short filaments and circular structures were
seen clustering together into aggregate assemblies (Figure 4B,
left panel). Introduction of I423D/K663D/M666D mutations
into the full-length MBP-MxBYRGK construct (MBP-MxBYRGK/
IKM) improved the solution behavior and rendered the protein
less prone to aggregation. Discrete particles of oligomers 30–
40 nm across were the majority among the structural assemblies
observed for this interface mutant (Figure 4B, right panel). This
observation is consistent with our results by size-exclusion chro-
matography, where MBP-MxBYRGK/IKM, MBP-MxBIKM, and
MBP-MxBIK primarily eluted as soluble dimers (Figures 4C and
5E), while MBP-MxB migrated as a higher-order assembly or
aggregate (Figure 4C).
We tested the requirement of higher-order oligomerization
for MxB antiviral function. Interface 1 mutants I423D, K663D,
M666D, and the I423D/K663D double mutant potently inhibited
HIV-1 infection (greater than 11-fold; Figure 4D). WT MxB andCell Host &interface 1mutants were expressed at similar levels as assessed
by western blotting (Figure 4E) and displayed similar subcellular
localization (Figure 4F). These results indicate that MxB
oligomerization through interface 1 is not critical for HIV-1
restriction.
MxB Directly Interacts with HIV-1 Capsid Assemblies
We initially probed MxB binding to HIV-1 capsid using HOS cell
lysates and recombinant A14C/E45C CA, which forms stable,
crosslinked tubular assemblies (Pornillos et al., 2009). The CA
assemblies are sufficiently large to pellet in an Eppendorf centri-
fuge (Matreyek et al., 2013), and capsid-binding partners can be
detected in a copelleting assay (Henning et al., 2014; Stremlau
et al., 2006). MxB binding was quantified as the percent of input
protein that copelleted in the presence of CA corrected for the
level of protein that nonspecifically pelleted in control reactions
that lacked CA. WT MxB-HA efficiently copelleted with CA as-
semblies (Figure 5A; 45% of input protein recovered versus
8% nonspecific pelleting). MxB interface 1 mutants K663D,
I423D/K663D, and M666D also interacted efficiently with CA,
yielding 27%, 40%, and 26% binding specificity, respectively
(Figure 5A). Hinge 1 mutant E681A displayed reduced binding
specificity compared to WT MxB (about 9.8% after background
correction). Interface 2 mutants M574D and Y651D were
more defective, yielding binding specificity values of about 2%Microbe 16, 627–638, November 12, 2014 ª2014 Elsevier Inc. 631
Figure 4. Higher-Order Oligomerization of MxB Is Not Required for Antiviral Activity
(A) Two adjacent MxB dimers representing formation of higher-order oligomers in two views (left) and a zoomed-in view of higher-order interface 1 (right).
Protomer 1 and 2 of one dimer are colored as in Figure 3 while protomer 10 and 20 are colored in dark gray and light gray, respectively. Important interface residues
are shown in sticks.
(B) Cryo-EM images of full-length MBP-MxB WT (6 mM) and the interface mutant MBP-MxBYRGK/IKM (3 mM). Short filaments (marked by arrows) and circular
structures (marked by triangles) are seen for WT MBP-MxB.
(C) Size-exclusion chromatography analysis of MBP-MxB1-715 (green), which elutes close to the void volume, and MBP-MxB1-715 IK/DD (red) and MBP-MxB1-715
IKM/DDD (blue), which elute at volumes corresponding to dimers. Inset, SDS-PAGE of peak fractions.
(D) Antiviral activities of WT and MxB interface 1 mutants. Results are an average of at least four independent experiments, with error bars denoting 95%
confidence intervals.
(E) Total mutant MxB expression levels relative to WT MxB (set to 1). Results are an average of at least three independent experiments, with error bars denoting
standard error.
(F) WT and mutant MxB localization as determined by confocal microscopy.
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binding to restriction of HIV-1 infection, the two parameters
were correlated by scatterplot analysis. The resulting negative
correlation yielded a Spearman rank correlation coefficient p
value of 0.028 (Figure 5B), indicating that the interaction between
MxB and CA plays a role in restriction of HIV-1 infection.
To evaluate if MxB interacts directly with capsid, binding as-
says were performed using recombinant MxB protein purified
from E. coli. The crystallization construct (MxB84YRGK) and full-
length mutant MBP-MxBYRGK/IKM proteins were used in these
experiments to ameliorate the aggregation tendency of the632 Cell Host & Microbe 16, 627–638, November 12, 2014 ª2014 Elswild-type protein. As before, binding specificity was assessed
by correcting for the level of pelleted MxB in control reactions
that lacked CA. Approximately 25% of MBP-MxBYRGK/IKM
cosedimented with CA after background (pelleted MxB without
CA) correction (Figure 5C). Although the comparison of this
result to the binding of WT MxB-HA in cell extracts should be
approached with a note of caution, the results nevertheless
indicate that cellular cofactors are not required for the binding
between MxB and HIV-1 CA. In contrast, only 9% of
MxB84YRGK cosedimented with CA (Figure 5C). Although this
level of residual binding was significantly greater than theevier Inc.
Figure 5. Interactions with Capsid Assemblies by WT and Mutant MxB Proteins
(A) Cell extracts containing HA-tagged MxB were tested for binding to crosslinked CA tubular assemblies. Pelleted proteins resolved by SDS-PAGE were
visualized by western blotting (MxB) or stained with Coomassie blue (CA). Results are an average of five independent experiments with standard errors plotted.
Lane indicators above the representative western blot: i, 20% of input cell lysate in absence of CA; , pellets from binding reactions in the absence of CA; +,
reactions in the presence of CA. Lane 1 of lower panel, 20% of input CA.
(B) Scatterplot of WT and mutant MxB-HA binding (x axis) versus normalized level of HIV-1 infectivity (y axis). Points denote the geometric mean of each data set.
The comparison exhibited a negative correlation with a significant Spearman rank correlation (p = 0.028).
(C) Binding of purified MxB (with or without CypA or CPSF6313-327), maltose binding protein (MBP) (negative control), or a region of TRIMCyp (CC-Cyp) (positive
control) to crosslinked CA assemblies. Total (T), soluble (S), and pellet (P) fractions resolved by SDS-PAGE were visualized with Coomassie staining and
quantified with ImageJ. Three CA variants were analyzed for binding: A14C/E45C (CA), A14C/E45C/G89V (G89V), and A14C/E45C/N74D (N74D). Quantification
of the binding, with standard errors, from three independent experiments is plotted below the gels. p values from two-sided, unequal variance t tests are shown
for the pelleting comparison for each MxB construct with or without CA.
(D) Visualization of the interaction of MxB constructs with HIV-1 CA tubes. Cryo-EM images of reaction mixtures containing crosslinked CA assemblies (10 mM)
and MBP-MxB1-715 YRGK/IKM (5 mM) or MBP-MxB84-715 YRGK/IKM (5 mM) shows additional protein density decorating the tubes (middle and right panels) that is not
observed in the control tubes without MxB (left). Substantially more decoration of the CA tubes occurs with the full-length MxB construct (middle) than with the
N-terminal truncation construct (right).
(E) Size-exclusion chromatograms of purified MBP-MxBYRGK/IKM (blue), crosslinked CA hexamers (red), and their mixture (green). CA hexamers and MBP-
MxBYRGK/IKM do not bind, as the elution profile of the mixture is the exact superposition of the individual ones. The SDS-PAGE analysis of the peaks (labeled 1, 2,
and 3) is shown.
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to full-length MBP-MxBYRGK/IKM copelleted with CA (p =
0.002). These data provide evidence of a direct interaction be-
tween MxB and HIV-1 capsid and indicate that the first 84
residues of MxB contribute to the interaction. This is consistent
with the previously published results showing the MxB N termi-Cell Host &nus is critical for HIV-1 restriction (Busnadiego et al., 2014; Gou-
jon et al., 2014; K.A.M. et al., unpublished data). At this point
we can only infer that the dimer is the basic CA binding unit of
MxB; multiple attempts to purify recombinant dimerization mu-
tants such as M574D failed to yield soluble protein for binding
studies.Microbe 16, 627–638, November 12, 2014 ª2014 Elsevier Inc. 633
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Structural Insight into HIV-1 Restriction by MxBAs certain CA mutations abolish MxB restriction of HIV-1, we
investigated whether some of these (G89V and N74D) alter
MxB’s ability to bind HIV-1 CA assemblies in vitro. The G89V
mutation abolishes CypA binding (Schaller et al., 2011) and elim-
inates MxB restriction of HIV-1 (Kane et al., 2013). The N74D
mutation abolishes CA binding to the capsid cofactor CPSF6
(Lee et al., 2010; Price et al., 2012) and reduces but does not
eliminate MxB’s ability to restrict HIV-1 (Kane et al., 2013). Inter-
estingly, neither of the two mutations reduced MxB binding to
the CA assemblies in our assay (Figure 5C). These results
show that these functionally important CA residues are not
required for MxB binding.
To further probe the involvement of these CA residues in MxB
binding, we tested whether the presence of CypA or a capsid-
binding peptide of CPSF6 (CPSF6313-327) altered the ability of
MBP-MxBYRGK/IKM to bind CA. Our results show MBP-
MxBYRGK/IKM binds to CA with similar affinity in the presence or
absence of these two CA-binding partners (Figure 5C). Because
we could not saturate the tubes with CypA and were uncertain if
the CPSF6313-327 peptide occupies all available binding sites, it is
not clear whether the binding events are mutually exclusive.
However, as we did not see an increase in pelleted MBP-
MxBYRGK/IKM in the presence of CypA or CPSF6313-327, these
factors do not appear to enhance MxB binding.
The interaction between MBP-MxBYRGK/IKM or MBP-
MxB84-715 YRGK/IKM and CA assemblies was additionally
analyzed by cryo-EM (Figure 5D). Inspection of the cryo-EM
images of the reaction mixtures shows distinct protein densities
decorating the CA tubes that are only seen in the presence of
the MxB constructs (Figure 5D). As expected, the decoration
of CA tubes by MBP-MxBYRGK/IKM was much more pronounced
than for MBP-MxB84-715 YRGK/IKM, confirming both direct protein
binding and the importance of the MxB N terminus in this
interaction.
To probe the oligomeric state of CA required for MxB binding,
we analyzed the ability of MxB to bind soluble CA hexamers.
We incubated purified MBP-MxBYRGK/IKM with crosslinked CA
hexamers and examined their interaction using size-exclusion
chromatography. No interaction was detected between the
two as MBP-MxBYRGK/IKM and CA hexamers eluted from the
size-exclusion column as two distinct peaks at positions corre-
sponding to those of the individual components (Figure 5E).
This result, together with those from the copelleting and cryo-
EM assays, suggests that MxB does not have appreciable affin-
ity for single CA hexamers but binds to capsid assemblies,
implying that MxB may function as a capsid pattern sensor
that only recognizes the assembled CA lattice.
DISCUSSION
MxB is a recently identified HIV-1 restriction factor whose mode
of inhibition is incompletely understood. The research presented
herein establishes a structural and biochemical framework for
understanding the mechanism by which MxB restricts HIV-1.
Our results reveal characteristics of MxB that are required for
its antiviral activity, uncover separate determinants for the func-
tions of MxB and the homologous MxA, and, importantly,
demonstrate a direct interaction between MxB and HIV-1 CA
that requires higher-order capsid assembly. These results pro-634 Cell Host & Microbe 16, 627–638, November 12, 2014 ª2014 Elsvide important insight into how MxB may bind viral capsid
and interfere with capsid uncoating-related processes to inhibit
HIV-1.
The structure and sequence of MxB and MxA are similar, but
the two proteins have different antiviral characteristics. These
proteins are dimers in solution, and our data show that, like
MxA, the dimerization of MxB is required for viral restriction.
Contrary to MxA’s mode of restriction that requires further multi-
merization, higher-order oligomerization of MxB is not critical for
HIV-1 restriction. Mutation of residues at the higher-order inter-
face 1 did not alter MxB activity (Figure 4D), while altering the
corresponding residues on MxA abolished its restriction ability
(Gao et al., 2010). This difference may be related to the presence
of a NLS in MxB. The NLS-mediated localization of MxB to the
nuclear envelope may increase its local concentration at the nu-
clear pore, which may mitigate the need for higher-order oligo-
mers to exert its antiviral effects. In addition, we show that
conformational coupling between the GTPase and the stalk
domain, which is important for regulation of GTPase activity
and antiviral function ofMxA, is not necessary inMxB (Figure 2E).
Our identification of MxB as a direct HIV-1 capsid-binding pro-
tein substantially advances our understanding of the mechanism
of HIV-1 restriction by MxB. Our data demonstrate that interac-
tion between MxB and CA is dependent on the first 83 residues
of MxB and does not require other host factors (Figure 5). It has
been well established that the N-terminal residues of MxB are
critical for its anti-HIV-1 activity (Busnadiego et al., 2014; Goujon
et al., 2014). This is partially attributed to the required nuclear
localization of MxB (Kane et al., 2013; K.A.M. et al., unpublished
data). Our results now show the N terminus of MxB is also critical
for its interaction with HIV-1 CA. This is consistent with the recent
report that the N-terminal domain of MxB (91 amino acids),
which includes residues downstream from the NLS, confers
HIV-1 restriction to MxA (Goujon et al., 2014). These results sug-
gest that the direct engagement between MxB and capsid is an
important step in the restriction of HIV-1 by MxB.
During the review of this work, Fricke et al. reported that
ectopically expressed MxB binds higher-order capsid assem-
blies in vitro and that MxB decreases the extent of HIV-1 capsid
uncoating during infection (Fricke et al., 2014). These results
agree with our finding that a direct interaction occurs between
MxB and capsid. In contrast, Fricke et al. concluded that multi-
merization of MxB is important for the interaction with the HIV-
1 core. Our crystal structure shows that the reported truncation
mutations (D572–715 and D623–715) removed the majority of
the stalk domain that is central to MxB dimer formation, and
the reported point mutation (L661K) seems likely to disrupt
MxB folding because it is located within the hydrophobic core
of the stalk. The reported multimerization-disrupting mutations
therefore likely disrupted MxB dimerization, which is consistent
with the importance of dimerization revealed in our study.
Our structural and binding studies provide important insight
into an HIV-1 capsid recognition. We observe binding of MxB
to capsid assemblies, but not individual CA hexamers (Figure 5).
This suggests thatMxB, like TRIM5 restriction factors, is a capsid
pattern sensor that recognizes higher-order CA assemblies (Per-
tel et al., 2011). This is further supported by data showing that CA
residues 207, 208, and 210, which are near the trimeric interface
of CA hexamers, are critical for MxB restriction (Busnadiegoevier Inc.
Figure 6. Conceptual Binding Model of the MxB Dimer to HIV Capsid
(A) The dimension of the MxB dimer matches the spacing (marked by the lines) between either trimers (3-fold axes marked by triangles) or dimers (2-fold axes
marked by eye-shaped symbols) of CA hexamers. TheMxB dimer (top) is colored with both the GTPase and the BSE domains in red and yellow, respectively, and
with the stalk domain of each protomer in green or cyan. The N terminus of MxB is indicated by an oval. The capsid model (bottom) was created by docking the
crystal structure of HIV-1 CA hexamer (PDB ID: 3H4E) to the EM map of HIV-CA helical tube (EMDB accession code: EMD-5136).
(B) Two orthogonal views of a possible bindingmode of theMxB dimer to the capsid at the interfaces of a trimer of CA hexamers. TheGTPase domains ofMxB are
oriented such that the N termini (ovals) of MxB can extend and interact with residues known to be important (207/210, asterisks) at the hexamer interfaces and the
sites (marked by the # signs) where binding of the CPIPB inhibitor led to competitive inhibition of MxB binding to capsid. The flexibility of the MxB N terminus and
the hinge regions may allow MxB to adjust to the changing curvature of the HIV-1 capsid. The pink-colored hexamers are removed in the side view for clarity.
(C) Potential MxB binding to the interfaces of a dimer of CA hexamers. The tan-colored hexamers are removed in the side view for clarity.
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important for theMxB-capsid interaction. These results, together
with our crystal structure, allow us to create a model of an MxB
dimer binding to the CA lattice (Figure 6). The stalk domains pro-
vide proper spacing over theCA lattice, as the distance is180 A˚
between the N termini of the dimer, which matches the distance
between the CA hexamer interfaces (Figure 6A). Each N terminus
is positioned near the interface between either trimers (Figure 6B)
or dimers (Figure 6C) of CA hexamers, in a location amenable to
binding. The predicted MxB-binding sites overlap with the bind-
ing site for the small molecule CPIPB inhibitor (referred to as
compound 1 in Lemke et al., 2013), which is consistent with
the report that this compound could competitively inhibit the
binding of ectopically expressed MxB to CA-nucleocapsid
tubular structures in vitro (Fricke et al., 2014). The hinge regions
and the potentially flexible N terminus of MxB provide plasticity
to adapt to the varying curvature of the CA core. Although the
majority of binding is likely provided by the MxB N terminus, its
GTPase domain and hinge 1 region may also contact the capsid.
This is consistent with our data that the N-terminal deletion
construct MxB84YRGK retained some binding to capsid (Figures
5C and 5D) and that hinge 1 mutations reduced the capsid inter-
action (Figures 5A and 5B). While this model does not provide
detailed information about the binding interfaces, it establishes
a framework for understanding and guiding future studies on
the interaction between MxB and HIV-1 capsid.
MxB likely functions as a critical player in a restriction
pathway involving other host factors that interact with HIV-1
capsid. The capsid-interaction events of MxB and some of
these factors, such as CypA and CPSF6, appear to be indepen-
dent (Figure 5C). Our data show that MxB binds to CA mutants
that abolish MxB’s antiviral activity, demonstrating that theCell Host &mutated CA residues are not critical for binding MxB (Figure 5C).
These CA mutations are important for binding of other cellular
factors including CypA, CPSF6, NUP153, and NUP358 (Lee
et al., 2010; Matreyek et al., 2013; Schaller et al., 2011). Further-
more, the presence of CypA or CPSF6313-327 does not enhance
MxB binding to CA assemblies (Figure 5C). These results sug-
gest that direct interactions between MxB and these CA-binding
proteins are not required, but instead MxB restriction may occur
at an independent step in a pathway that is dependent on
proper interaction between other cellular factors and CA. Alter-
natively, MxB may alter the affinity of other host factors for the
capsid or the nature of their binding such that they become
inhibitory. Taken together, MxB may be able to directly modu-
late or affect other cellular factors to control the stability of the
HIV-1 capsid. This, coupled with the localization of MxB to the
nuclear rim, suggests that MxB may function to interfere with
the proper uncoating and translocation of the HIV-1 capsid
core near the cell nucleus.
EXPERIMENTAL PROCEDURES
Cloning and Expression
MxBFL was cloned into pCDF Duet (Novagen) with an N-terminal MBP tag.
MxB84-715 was cloned into pETDUET-1 (Novagen) with an N-terminal 6xHis
tag. Proteins were overexpressed in E. coli BL21(DE3) cells at 18C for 18 hr
by induction with 0.5 mM IPTG. MxB with a C-terminal HA was cloned into
the retroviral transfer vector pLPCX (Clontech). Mutations were made by Quik-
Change site-directed mutagenesis (Stratagene) on MxB vector templates.
Protein Purification
Bacterial cells were harvested by centrifugation at 5,000 rpm. Cells were re-
suspended in lysis buffer (50 mM Tris [pH 8.0], 500 mM NaCl, 20 mM imid-
azole, 0.1 mM TCEP) and lysed using a microfluidizer. Cell debris was clarified
by centrifugation at 15,000 rpm for 45 min for 6xHis-tagged construct and atMicrobe 16, 627–638, November 12, 2014 ª2014 Elsevier Inc. 635
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were purified by MBP affinity and size-exclusion chromatography. 6xHis
MxB84-715 constructs were purified by nickel affinity, anion exchange, and
size-exclusion chromatography and were analyzed at each step by SDS-
PAGE.
Crystallization and Data Collection
Crystallization of the protein was performed by the microbatch under-oil
method (Chayen et al., 1990). One microliter of the protein solution (2 mg/ml
in 50 mM Tris [pH 8], 150 mMNaCl, 0.1 mM TCEP), 2 mMDTT, and the precip-
itant solution (0.1 M MES [pH 6.5], 5% PEG4000, 10% 2-propanol, 0.05 M
MgCl) weremixed. Crystals formed at RTwere cryoprotected using the precip-
itant solution with 30% glycerol before freezing in liquid nitrogen. Diffraction
data were collected at the NE-CAT beamline 24ID-E at the Advanced Photon
Source and the beamline X25 at the National Synchrotron Light Source. The
data collection statistics are in Table 1.
Structure Determination and Refinement
The structure was solved using the GTPase domain and the stalk domain of
MxA (Gao et al., 2010, 2011) as search models for molecular replacement us-
ing the CCP4 program Phaser (CCPN4, 1994; McCoy et al., 2007; Vagin and
Teplyakov, 2000). Iterative rounds of model building in COOT (Emsley and
Cowtan, 2004) and refinement with REFMAC5 (Murshudov et al., 1997)
and PHENIX (Adams et al., 2010) were carried out. Data sharpening was per-
formed (Liu and Xiong, 2014) to facilitate model building. The final model has
an Rwork/Rfree of 26.5%/29.9%. The refinement statistics are summarized in
Table 1.
Cells and Infectivity Assays
HOS cells were maintained in Dulbecco’s modified Eagle’s medium (Invitro-
gen) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin,
and 0.1 mg/ml streptomycin. HOS cells stably transduced with LPCX transfer
vectors were selected and maintained with 2 mg/ml puromycin.
Cells seeded onto 48-well plates were infected with various reporter viruses
as described (Matreyek et al., 2013). Percentages of GFP-positive cells were
determined 48 hr postinfection using a FACSCanto flow cytometer equipped
with FACSDIVA software. Virus inoculates were adjusted to yield 40%
GFP-positive cells in control samples that contained empty LPCX.
Immunofluorescence Confocal Microscopy
Cells cultured on Nunc Lab-Tek II chamber slides (Thermo Scientific) were
fixed with 4% paraformaldehyde for 10 min, washed with phosphate buffered
saline (PBS), and permeabilized with ice-cold MeOH for 10 min. The permea-
bilized cells were blocked with PBS containing 10% FBS for 30 min and
stained with 1:300 dilution of anti-HA antibody 16b12 (Covance). After a
30 min wash with PBS, the cells were incubated for 1 hr with a 1:1,000 dilution
of an Alexa Fluor 555-conjugated goat anti-mouse IgG antibody (Invitrogen),
as well as Hoescht 33342 (Invitrogen) diluted to a concentration of 1 mg/ml. Af-
ter an additional 30 min wash with PBS, the samples were covered with
mounting medium (150 mM NaCl, 25 mM Tris [pH 8.0], 0.5% N-propyl gallate,
and 90% glycerol). The processed samples were analyzed on a Nikon Eclipse
spinning disk confocal microscope at the Dana-Farber Cancer Institute
Confocal and Light Microscopy core.
Western Blotting
Cells pelleted at 3003 g were resuspended in PBS supplemented to contain
0.2% NP-40 and 10 U/ml Turbo DNase in 1X Turbo DNase buffer (Ambion).
After 30 min on ice, mixtures were adjusted to contain 62.5 mM Tris (pH
6.8), 2% SDS, 10% glycerol, 5% b-mercaptoethanol, 100 mM DTT, and
0.001% bromophenol blue. Samples heated at 100C were separated on
Tris-glycine polyacrylamide gels and transferred to polyvinylidene fluoride
membrane, and MxB-HA was detected with a 1:2,000 dilution of HRP-conju-
gated 3F10 antibody (Roche). b-actin was detected with a 1:10,000 dilution of
HRP-conjugated antibody clone AC-15 (Sigma). The amount of MxB-HA or
b-actin signal in each sample was quantitated relative to the level of each
signal in amatchedWTMxB-expressing sample, which was set to 1, using Im-
age Lab 4.1 (Bio-Rad). The MxB expression ratio was calculated by dividing
the MxB-HA signal with that of b-actin.636 Cell Host & Microbe 16, 627–638, November 12, 2014 ª2014 ElsCA Binding Assay with Cell Lysate
Recombinant HIV-1 CA A14C/E45C was expressed in E. coli and purified as
described previously (Pornillos et al., 2009). Crosslinked CA assemblies
were prepared by direct dilution into assembly buffer (50 mM Tris [pH 8.0],
1 M NaCl, 0.2 mM b-mercaptoethanol), incubation at 37C for 1 hr, and dilu-
tion to the final concentration of 4 mg/ml. HOS cells expressing WT or
mutant MxB-HA were lysed in buffer A (50 mM Tris [pH 7.5], 150 mM
NaCl, 0.5% NP40, 1x complete protease inhibitor [Roche]), and lysates
were clarified by centrifugation at 21,0003 g at 4C. Approximately 20 mg
of lysate was mixed with assembled CA, yielding final concentrations of
64 mM CA and 5 mg/ml total cell protein, followed by incubation at RT for
30 min. Binding reactions were centrifuged through a 35% sucrose cushion
in PBS at 21,0003 g at 4C for 30 min. The supernatant was removed, and
the pellet was resuspended in buffer lacking reducing agent. MxB-HA was
detected by western blotting whereas CA was detected by staining with
Coomassie blue.
CA Binding Assays with Purified Proteins
Crosslinked CA (A14C/E45C) tubes were dialyzed overnight at 4C into as-
sembly buffer (1 M NaCl, 50 mM Tris [pH 8.0]), followed by dialysis into binding
buffer (150 mM NaCl, 50 mM Tris [pH 8.0]) (Pornillos et al., 2009). MxB and
control proteins were spun at 20,0003 g for 30 min at 4C. MxB (10 mM) and
control proteins in 10.5 ml were added to 10.5 ml CA tubes and incubated at
RT for 1 hr. Subsequently, 7 ml aliquots were withdrawn. The remaining was
pelleted at 20,0003 g for 30 min at 4C. Total, supernatant, and pellet samples
were analyzed by SDS-PAGE. Copelleting experiments with CypA and
CPSF6313-327 were performed as described with 30 mM CypA and 200 mM
CPSF6313-327.
The interaction between MxB and crosslinked CA (A14C/E45C) hexamers
was examined by size-exclusion chromatography. CA hexamers were assem-
bled as described previously (Pornillos et al., 2009). Samples (200 ml) of MBP-
MxBYRGK/IKM (11.25 mM), CA hexamers (55 mM), and their mixtures were run on
a Superdex 200 10/300 GL. Peak fractions were analyzed by SDS-PAGE. Gels
were quantified with ImageJ.
Cryo-EM
A sample (3 ml) of purified MxB variants or the mixture from the binding assays
was applied onto a glow-discharged Quantifoil (R2/2) grid. Excess fluid on the
grid was blotted with filter paper and then the grid was rapidly frozen in liquid
ethane using a homemade manual freezing device. Frozen grids were trans-
ferred into a Gatan cryoholder and examined with a FEI Tecnai 200 kV Field
Emission Gun transmission electron microscope equipped with a Gatan 4K
3 4K charge-coupled device camera. Low-dose (20 e/A˚2) images were re-
corded at nominal magnifications of either 29,0003 or 50,0003 at underfocus
values of 2–4 mm.
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